{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:34:57Z","timestamp":1788255297349,"version":"build-2803163510"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ferroptosis is one of the main mechanisms of sorafenib against hepatocellular carcinoma (HCC). Epithelial-mesenchymal transition (EMT) plays an important role in the heterogeneity, tumor metastasis, immunosuppressive microenvironment, and drug resistance of HCC. However, there are few studies looking into the relationship between ferroptosis and EMT and how they may affect the prognosis of HCC collectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We downloaded gene expression and clinical data of HCC patients from the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases for prognostic model construction and validation respectively. The Least absolute shrinkage and selection operator (LASSO) Cox regression was used for model construction. The predictive ability of the model was assessed by Kaplan\u2013Meier survival analysis and receiver operating characteristic (ROC) curve. We performed the expression profiles analysis to evaluate the ferroptosis and EMT state. CIBERSORT and single-sample Gene Set Enrichment Analysis (ssGSEA) methods were used for immune infiltration analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of thirteen crucial genes were identified for ferroptosis-related and EMT-related prognostic model (FEPM) stratifying patients into two risk groups. The high-FEPM group had shorter overall survivals than the low-FEPM group (p&amp;lt;0.0001 in the TCGA cohort and p&amp;lt;0.05 in the ICGC cohort). The FEPM score was proved to be an independent prognostic risk factor (HR&amp;gt;1, p&amp;lt;0.01). Furthermore, the expression profiles analysis suggested that the high-FEPM group appeared to have a more suppressive ferroptosis status and a more active EMT status than the low- FEPM group. Immune infiltration analysis showed that the myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs) were highly enriched in the high-FEPM group. Finally, a nomogram enrolling FEPM score and TNM stage was constructed showing outstanding predictive capacity for the prognosis of patients in the two cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, we developed a ferroptosis-related and EMT-related prognostic model, which could help predict overall survival for HCC patients. It might provide a new idea for predicting the response to targeted therapies and immunotherapies in HCC patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1076045","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T06:53:35Z","timestamp":1671087215000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Prognostic prediction and immune infiltration analysis based on ferroptosis and EMT state in hepatocellular carcinoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhaochen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huahu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dute","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengshuo","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30427-1","article-title":"Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the global burden of disease study 2017","volume":"394","author":"Zhou","year":"2019","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3389\/10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28159","article-title":"Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib","volume":"133","author":"Louandre","year":"2013","journal-title":"Int J Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/hep.28574","article-title":"Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis","volume":"64","author":"Sun","year":"2016","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26224","article-title":"Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von hippel-lindau tumor suppressor-dependent HIF-1\u03b1 inhibition in hepatocellular carcinoma","volume":"57","author":"Liang","year":"2013","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"EMT: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jhep.2016.05.007","article-title":"Role of epithelial to mesenchymal transition in hepatocellular carcinoma","volume":"65","author":"Giannelli","year":"2016","journal-title":"J Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108647","article-title":"Dynamic EMT: a multi-tool for tumor progression","volume":"40","author":"Brabletz","year":"2021","journal-title":"EMBO J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.44","article-title":"CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4459","article-title":"Tumor immune microenvironment during epithelial-mesenchymal transition","volume":"27","author":"Taki","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"102610","DOI":"10.1016\/j.ebiom.2019.102610","article-title":"The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma","volume":"51","author":"Xia","year":"2020","journal-title":"EBioMedicine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2012.10.021","article-title":"Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth","volume":"329","author":"van Malenstein","year":"2013","journal-title":"Cancer letters."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature23007","article-title":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","volume":"547","author":"Viswanathan","year":"2017","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","first-page":"102149","DOI":"10.1016\/j.redox.2021.102149","article-title":"HDAC inhibition induces EMT and alterations in cellular iron homeostasis to augment ferroptosis sensitivity in SW13 cells","volume":"47","author":"Oliveira","year":"2021","journal-title":"Redox Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01676-x","article-title":"DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the hippo pathway","volume":"40","author":"Lin","year":"2021","journal-title":"Oncogene"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.822315","article-title":"Single-cell RNA-seq reveals the promoting role of ferroptosis tendency during lung adenocarcinoma EMT progression","volume":"9","author":"Yao","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3015710","DOI":"10.1155\/2021\/3015710","article-title":"Ferritinophagic flux was a driving force in determination of status of EMT, ferroptosis, and NDRG1 activation in action of mechanism of 2-pyridylhydrazone dithiocarbamate s-acetic acid","volume":"2021","author":"Li","year":"2021","journal-title":"J Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3920664","DOI":"10.1155\/2022\/3920664","article-title":"Ferritinophagy-mediated ferroptosis and activation of Keap1\/Nrf2\/HO-1 pathway were conducive to EMT inhibition of gastric cancer cells in action of 2,2\u2019-di-pyridineketone hydrazone dithiocarbamate butyric acid ester","volume":"2022","author":"Guan","year":"2022","journal-title":"Oxid Med Cell Longevity"},{"key":"B24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cytogfr.2022.01.006","article-title":"Crosstalk between ferroptosis and the epithelial-mesenchymal transition: Implications for inflammation and cancer therapy","volume":"64","author":"Ebrahimi","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","article-title":"Regularization paths for generalized linear models via coordinate descent","volume":"33","author":"Friedman","year":"2010","journal-title":"J Stat Softw"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.809672","article-title":"Construction and validation of a combined ferroptosis and hypoxia prognostic signature for hepatocellular carcinoma","volume":"8","author":"Wen","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.596679","article-title":"Development and validation of a combined ferroptosis and immune prognostic classifier for hepatocellular carcinoma","volume":"8","author":"Liu","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36183","article-title":"Biomarkers for epithelial-mesenchymal transitions","volume":"119","author":"Zeisberg","year":"2009","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.gene.2017.03.005","article-title":"HSPA5 gene encoding Hsp70 chaperone BiP in the endoplasmic reticulum","volume":"618","author":"Wang","year":"2017","journal-title":"Gene"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1979","article-title":"HSPA5 regulates ferroptotic cell death in cancer cells","volume":"77","author":"Zhu","year":"2017","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-855955\/v1","article-title":"HSPA5 repressed ferroptosis to promote colorectal cancer development by maintaining GPX4 stability","volume":"69","author":"Wang","year":"2022","journal-title":"Neoplasma"},{"key":"B36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/s13046-019-1413-7","article-title":"Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK\/ATF4\/HSPA5 pathway in glioma cells","volume":"38","author":"Chen","year":"2019","journal-title":"J Exp Clin Cancer Res: CR."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvy047","article-title":"Involvement of partial EMT in cancer progression","volume":"164","author":"Saitoh","year":"2018","journal-title":"J Biochem"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1016\/j.devcel.2021.11.006","article-title":"Distinct contributions of partial and full EMT to breast cancer malignancy","volume":"56","author":"L\u00fc\u00f6nd","year":"2021","journal-title":"Dev Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-016-2818-7","article-title":"Cytokeratin 18 is necessary for initiation of TGF-\u03b21-induced epithelial-mesenchymal transition in breast epithelial cells","volume":"423","author":"Jung","year":"2016","journal-title":"Mol Cell Biochem"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.12.006","article-title":"Vimentin and cytokeratin: Good alone, bad together","volume":"86","author":"Kuburich","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2021.06.024","article-title":"An immunogenomic signature for molecular classification in hepatocellular carcinoma","volume":"25","author":"Zhuang","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2021.06.014","article-title":"Ferroptosis in the tumor microenvironment: perspectives for immunotherapy","volume":"27","author":"Xu","year":"2021","journal-title":"Trends Mol Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/s41467-018-03966-7","article-title":"Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation","volume":"9","author":"Taki","year":"2018","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12098","article-title":"ZEB1-regulated inflammatory phenotype in breast cancer cells","volume":"11","author":"Katsura","year":"2017","journal-title":"Mol Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1263412","article-title":"The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200","volume":"6","author":"Noman","year":"2017","journal-title":"Oncoimmunology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1038\/ncomms6241","article-title":"Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression","volume":"5","author":"Chen","year":"2014","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S172417","article-title":"CD4(+) CD25(+) regulatory T cells promote hepatocellular carcinoma invasion via TGF-\u03b21-induced epithelial-mesenchymal transition","volume":"12","author":"Shi","year":"2019","journal-title":"OncoTargets Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0478-3","article-title":"Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma","volume":"42","author":"Li","year":"2021","journal-title":"Acta Pharmacol Sinica"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1076045\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T06:53:39Z","timestamp":1671087219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1076045\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2022.1076045"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1076045","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]},"article-number":"1076045"}}